Inventor · disambiguated record
Karen Chandross
Also filed as: CHANDROSS KAREN
8 granted patents·10 pending applications·9 citations·filing 2003–2015
78Inventor score
Files withAVENTIS PHARMA INC9SANOFI AVENTIS4SANOFI AVENTIS DEUTSCHLAND2AVENTIS PARMACEUTICALS INC1CAO JAMES1
Top patents by PatentIndex Score
18 records- 0178US7709481B2Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticalsSANOFI AVENTIS·Filed 2008·Granted May 4, 2010·4 cites·30 claims
- 0276US7638539B21, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic diseaseAVENTIS PHARMA INC·Filed 2006·Granted Dec 29, 2009·2 cites·2 claims
- 0374US7655679B2Derivatives of 2-aminothiazoles and 2-amino-oxazoles, processes for their preparation and their use as pharmaceutical compositionsSANOFI AVENTIS·Filed 2008·Granted Feb 2, 2010·2 cites·10 claims
- 0466US7872032B21, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereofAVENTIS PARMACEUTICALS INC·Filed 2009·Granted Jan 18, 2011·1 cites·4 claims
- 0559US7851493B2Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticalsSANOFI AVENTIS·Filed 2009·Granted Dec 14, 2010·0 cites·21 claims
- 0658US7709509B2Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonistsSANOFI AVENTIS DEUTSCHLAND·Filed 2008·Granted May 4, 2010·0 cites·32 claims
- 0756US7834030B2Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereofSANOFI AVENTIS·Filed 2008·Granted Nov 16, 2010·0 cites·32 claims
- 0851US2007179191A1Oxadiazolones and derivatives thereof as ppar delta agonistsSANOFI AVENTIS DEUTSCHLAND·Filed 2006·Application pending·0 cites
- 0950US2007249706A1Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms)AVENTIS PHARMA INC·Filed 2007·Application pending·0 cites
- 1046US2016066550A1Animal Model Expressing Luciferase under Control of the Myelin Basic Protein Promoter (MBP-luci) and Use of the Model for Bioluminescence In Vivo ImagingSANOFI SA·Filed 2015·Application pending·0 cites
- 1146US2004033226A1Osteopontin, oligodendrocytes and myelinationAVENTIS PHARMA INC·Filed 2003·Application pending·0 cites
- 1245US7576109B21,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereofAVENTIS PHARMA INC·Filed 2006·Granted Aug 18, 2009·0 cites·15 claims
- 1340US2007149580A1Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseasesAVENTIS PHARMA INC·Filed 2006·Application pending·0 cites
- 1439US2013117868A1Animal Model Expressing Luciferase under Control of the Myelin Basic Protein Promoter (MBP-luci) and Use of the Model for Bioluminescence In Vivo ImagingCAO JAMES·Filed 2010·Application pending·0 cites
- 1539US2007249732A1Use of certain phenyl napthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms)AVENTIS PHARMA INC·Filed 2007·Application pending·0 cites
- 1638US2007280885A1Methods Of Treating Demyelinating DisordersAVENTIS PHARMA INC·Filed 2005·Application pending·0 cites
- 1737US2007225330A1Use of certain phenyl-naphthyl compounds that do not have significant affinity to er alpha or er beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosisAVENTIS PHARMA INC·Filed 2007·Application pending·0 cites
- 1837US2008033005A1Methods for the treatment of multiple sclerosisAVENTIS PHARMA INC·Filed 2007·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →